comparemela.com

Latest Breaking News On - Uveal melanoma - Page 5 : comparemela.com

Solid Cancer Approvals from Summer 2023

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

Eloise chapman davisAugust akeegaDrug administrationHepzato kitWeill cornell medicineUveal melanomaProstate cancerColorectal cancerEndometrial cancer

Blue Apron Holdings (NASDAQ: APRN) Charts Path to Profitability in Q2 2023: Debt Elimination and Strategic Transaction

A significant turnaround materialized for Blue Apron (NYSE: APRN), sparking unseen investor support: a brief overview on developments.

Gerard michelVojislav vukovicAccess programNational comprehensive cancer networkDelcath systems incDelcath systemsRight nowExpanded access programRisk evaluationMitigation strategyChief medical officerPrivate investmentPublic equityHepatic delivery systemPercutaneous hepatic perfusionUveal melanoma

Delcath Systems (NASDAQ: DCTH) HEPZATO KIT Achieves FDA Approval: A Pivotal Step in Liver Cancer Treatment

A deconstructed view on Delcath Systems' (NASDAQ: DCTH) latest FDA approval and key points that are important for investors to understand.

Vojislav vukovicGerard michelAccess programDelcath systems incNational comprehensive cancer networkDelcath systemsRight nowExpanded access programRisk evaluationMitigation strategyChief medical officerPrivate investmentPublic equityHepatic delivery systemPercutaneous hepatic perfusionUveal melanoma

FDA Approves HEPZATO KIT for Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

The FDA has approved HEPZATO KIT (melphalan/Hepatic Delivery System) for use in the treatment of select patients with unresectable hepatic-dominant metastatic uveal melanoma.

Vojislav vukovicGerard michelDelcath systems incDelcath systemsHepzato kitUveal melanoma

FDA Approves Hepzato Kit for Metastatic Uveal Melanoma

The Hepzato Kit is a direct-to-liver therapy for patients with uveal melanoma with hepatic metastases.

Vojislav vukovicAccess programDrug administrationNational comprehensive cancer networkHepzato kitDelcath systemsExpanded access programRisk evaluationMitigation strategyUveal melanoma

vimarsana © 2020. All Rights Reserved.